The Next Big Drugs to Keep Our... Ear On?


Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.

In this week's installment, Motley Fool health care analyst Brenton Flynn discusses talk from a recent Reuters article, suggesting that hearing loss may actually be the next big target for big pharma. As it becomes harder and harder to find diseases affecting large patient populations that companies can develop game-changing drugs for, some see the hearing loss space as a huge potential market. It has normally been targeted only by medical devices such as hearing aids, but several big pharma companies are now working to develop treatments, and Pfizer even has a drug in clinical trials.

Investing in the next big thing in biotech and pharma can is one way to generate solid returns, but the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article The Next Big Drugs to Keep Our... Ear On? originally appeared on

Brenton Flynn, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.